Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Drugs and Therapy
Erschienen in: Cardiovascular Drugs and Therapy 6/2022

15.09.2021 | COVID-19 | Original Article Zur Zeit gratis

Efficacy of Statin Therapy in Patients with Hospital Admission for COVID-19

verfasst von: Daein Choi, Qinzhong Chen, Sascha N. Goonewardena, Hannah Pacheco, Priscilla Mejia, Robin L. Smith, Robert S. Rosenson

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

COVID-19 is characterized by dysfunctional immune responses and metabolic derangements, which in some, lead to multi-organ failure and death. Statins are foundational lipid-lowering therapeutics for cardiovascular disease and also possess beneficial immune-modulating properties. Because of these immune-modulating properties, some have suggested their use in COVID-19. We sought to investigate the association between statin use and mortality in patients hospitalized with COVID-19.

Methods

Five thousand three hundred seventy-five COVID-19 patients admitted to Mount Sinai Health System hospitals in New York between February 27, 2020, and December 3, 2020, were included in this analysis. Statin use was classified as either non-user, low-to-moderate-intensity user, or high-intensity user. Multivariate Cox proportional hazards models were used to evaluate in-hospital mortality rate. Considered covariates were age, sex, race, and comorbidities.

Results

Compared to non-statin users, both low-to-moderate-intensity (adjusted hazard ratio; aHR 0.62, 95% confidential intervals; CI 0.51–0.76) and high-intensity statin users (aHR 0.53, 95% CI 0.43–0.65) had a reduced risk of death. Subgroup analysis of 723 coronary artery disease patients showed decreased mortality among high-intensity statin users compared to non-users (aHR 0.51, 95% CI 0.36–0.71).

Conclusions

Statin use in patients hospitalized with COVID-19 was associated with a reduced in-hospital mortality. The protective effect of statin was greater in those with coronary artery disease. These data support continued use of statin therapy in hospitalized patients with COVID-19. Clinical trials are needed to prospectively determine if statin use is effective in lowering the mortality in COVID-19 and other viral infections.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Pinney SP, Giustino G, Halperin JL, Mechanick JI, Neibart E, Olin JW, et al. Coronavirus historical perspective, disease mechanisms, and clinical outcomes: JACC focus seminar. J Am Coll Cardiol. 2020;76:1999–2010.CrossRefPubMedPubMedCentral
3.
Giustino G, Pinney SP, Lala A, Reddy VY, Johnston-Cox HA, Mechanick JI, et al. Coronavirus and cardiovascular disease, myocardial injury, and arrhythmia: JACC focus seminar. J Am Coll Cardiol. 2020;76:2011–23.CrossRefPubMedPubMedCentral
4.
Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. COVID-19 in critically ill patients in the Seattle region - case series. N Engl J Med. 2020;382:2012–22.CrossRefPubMed
5.
Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–10.CrossRefPubMedPubMedCentral
6.
Colantonio LD, Shannon ED, Orroth KK, Zaha R, Jackson EA, Rosenson RS, Exter J, Mues KE, Muntner P. Ischemic event rates in very-high-risk adults. J Am Coll Cardiol. 2019;74:2496–507.CrossRefPubMed
7.
Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, et al. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost. 2020;120:1004–24.CrossRefPubMedPubMedCentral
8.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.CrossRefPubMed
9.
10.
Kong F, Ye B, Lin L, Cai X, Huang W, Huang Z. Atorvastatin suppresses NLRP3 inflammasome activation via TLR4/MyD88/NF-kappab signaling in PMA-stimulated THP-1 monocytes. Biomed Pharmacother. 2016;82:167–72.CrossRefPubMed
11.
Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. Sars-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280 e278.CrossRefPubMedPubMedCentral
12.
Shin YH, Min JJ, Lee JH, Kim EH, Kim GE, Kim MH, et al. The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts. Heart Vessels. 2017;32:618–27.CrossRefPubMed
13.
Tikoo K, Patel G, Kumar S, Karpe PA, Sanghavi M, Malek V, et al. Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications. Biochem Pharmacol. 2015;93:343–51.CrossRefPubMed
14.
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the sars coronavirus. Nature. 2003;426:450–4.CrossRefPubMedPubMedCentral
15.
Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, et al. Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol. 2017;70:1290–301.CrossRefPubMed
16.
Daniels LB, Sitapati AM, Zhang J, Zou J, Bui QM, Ren J, et al. Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients. Am J Cardiol. 2020;136:149–55.CrossRefPubMedPubMedCentral
17.
Gupta A, Madhavan MV, Poterucha TJ, DeFilippis EM, Hennessey JA, Redfors B, et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nat Commun. 2021;12:1325.CrossRefPubMedPubMedCentral
18.
Lohia P, Kapur S, Benjaram S, Mir T. Association between antecedent statin use and severe disease outcomes in COVID-19: a retrospective study with propensity score matching. J Clin Lipidol. 2021;15:451–9.CrossRefPubMedPubMedCentral
19.
Daniels LB, Ren J, Kumar K, Bui QM, Zhang J, Zhang X, et al. Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: findings from the American Heart Association’s COVID-19 cardiovascular disease registry. PLoS One. 2021;16:e0254635.CrossRefPubMedPubMedCentral
20.
Saeed O, Castagna F, Agalliu I, Xue X, Patel SR, Rochlani Y, et al. Statin use and in-hospital mortality in patients with diabetes mellitus and covid-19. J Am Heart Assoc. 2020;9:e018475.CrossRefPubMedPubMedCentral
21.
Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with covid-19. Cell Metab. 2020;32:176-187 e174.CrossRefPubMedPubMedCentral
22.
23.
Butt JH, Gerds TA, Schou M, Kragholm K, Phelps M, Havers-Borgersen E, et al. Association between statin use and outcomes in patients with coronavirus disease 2019 (covid-19): a nationwide cohort study. BMJ Open. 2020;10:e044421.CrossRefPubMed
24.
De Spiegeleer A, Bronselaer A, Teo JT, Byttebier G, De Tre G, Belmans L, et al. The effects of ARBs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residents. J Am Med Dir Assoc. 2020;21:909-914 e902.CrossRefPubMedPubMedCentral
25.
Choi D, Choi S, Kim H, Kim K, Kim N, Ko A, et al. Impact of continuity of care on cardiovascular disease risk among newly-diagnosed hypertension patients. Sci Rep. 2020;10:19991.CrossRefPubMedPubMedCentral
26.
Kozma CM, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: Implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence. 2013;7:509–16.CrossRefPubMedPubMedCentral
27.
Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11:449–57.PubMed
28.
Prasad V, Jena AB. Prespecified falsification end points: can they validate true observational associations? JAMA. 2013;309:241–2.CrossRefPubMed
29.
Wimmer NJ, Resnic FS, Mauri L, Matheny ME, Yeh RW. Comparison of transradial versus transfemoral percutaneous coronary intervention in routine practice: evidence for the importance of “falsification hypotheses” in observational studies of comparative effectiveness. J Am Coll Cardiol. 2013;62:2147–8.CrossRefPubMed
30.
Oh TK, Song I, Jeon YT. Statin therapy and the risk of COVID-19: a cohort study of the national health insurance service in South Korea. J Pers Med. 2021;11(2):116.CrossRefPubMedPubMedCentral
31.
Hariyanto TI, Kurniawan A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020;14:1613–5.CrossRefPubMedPubMedCentral
32.
Hariyanto TI, Kurniawan A. Statin and outcomes of coronavirus disease 2019 (covid-19): a systematic review, meta-analysis, and meta-regression. Nutr Metab Cardiovasc Dis. 2021;31:1662–70.CrossRefPubMedPubMedCentral
33.
Pal R, Banerjee M, Yadav U, Bhattacharjee S. Statin use and clinical outcomes in patients with COVID-19: an updated systematic review and meta-analysis. Postgrad Med J. 2021. postgradmedj-2020-139172.
34.
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5.CrossRefPubMedPubMedCentral
35.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.CrossRefPubMedPubMedCentral
36.
37.
38.
Totura AL, Whitmore A, Agnihothram S, Schafer A, Katze MG, Heise MT, et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. mBio. 2015;6:e00638-00615.CrossRefPubMedPubMedCentral
39.
Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131:1006–12.CrossRefPubMed
40.
McAuley DF, Laffey JG, O’Kane CM, Perkins GD, Mullan B, Trinder TJ, et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med. 2014;371:1695–703.CrossRefPubMed
41.
Vandermeer ML, Thomas AR, Kamimoto L, Reingold A, Gershman K, Meek J, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis. 2012;205:13–9.CrossRefPubMed
42.
Roccaforte V, Daves M, Lippi G, Spreafico M, Bonato C. Altered lipid profile in patients with COVID-19 infection. J Lab Precis Med. 2021;6:2–2.CrossRef
Metadaten
Titel
Efficacy of Statin Therapy in Patients with Hospital Admission for COVID-19
verfasst von
Daein Choi
Qinzhong Chen
Sascha N. Goonewardena
Hannah Pacheco
Priscilla Mejia
Robin L. Smith
Robert S. Rosenson
Publikationsdatum
15.09.2021
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 6/2022
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-021-07263-2

Weitere Artikel der Ausgabe 6/2022

Cardiovascular Drugs and Therapy 6/2022 Zur Ausgabe

Correction

Correction to: Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease

Original Article

K-80003 Inhibition of Macrophage Apoptosis and Necrotic Core Development in Atherosclerotic Vulnerable Plaques

Editorial

Is Aspirin Loading Before Primary Percutaneous Coronary Intervention for Patients with ST-Elevation Myocardial Infarction Necessary?

Original Article

Influence of Moxonidine and Bisoprolol on Morphofunctional Condition of Arterial Wall and Telomerase Activity in Postmenopausal Women with Arterial Hypertension and Osteopenia. The Results from a Moscow Randomized Study

Original Article

SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes

Editorial

Dual Anti-platelet Therapy After Transcatheter Aortic Valve Implantation: Double Trouble?

Passend zum Thema

ANZEIGE

IPD-Fallzahlen & Pneumokokken-Impfung bei Kindern in Deutschland

Das Niveau der postpandemischen Fallzahlen für invasive Pneumokokken-Erkrankungen (IPD) ist aus Sicht des Referenz-Zentrums für Streptokokken in Aachen alarmierend [1]. Wie sich die monatlichen IPD-Fallzahlen bei Kindern und Jugendlichen von Juli 2015 bis März 2023 entwickelt haben, lesen Sie hier.

ANZEIGE

HPV-Impfung: Auch für junge Erwachsene sinnvoll und wichtig

Auch nach dem 18. Lebensjahr kann eine HPV-Impfung sinnvoll und wichtig sein. Viele gesetzliche Krankenkassen übernehmen die Kosten auch zu einem späteren Zeitpunkt noch.

ANZEIGE

Impfstoffe – Krankheiten vorbeugen, bevor sie entstehen

Seit mehr als 130 Jahren entwickelt und produziert MSD Impfstoffe für alle Altersgruppen. Hier finden Sie nützliche Informationen und Praxismaterialien rund um das Thema Impfen.

MSD Sharp & Dohme GmbH
Bildnachweise